Long-horizon oncology environments for model evaluation

Cancer treatment is sequential.

We build synthetic cases where models must use molecular data, treatment history and changing patient state.

Initial focus: precision oncology and multi-omics.

Team
Environment Engineering state · tools · transitions
Evaluation Engineering verification · counterfactuals
Senior Oncology Specialist MD General Medicine · DM Oncology

OncoWorld · Kochi, India
Sonu Babu, CEO · sonu@oncoworld.tech

Research programs

Five oncology problems where sequential state, resistance and evidence matter.
01
Precision Oncology + Multi-omics
NGS, driver identification, resistance mechanisms and longitudinal reassessment.
02
TP53
Target discovery, pathway dependencies and synthetic-lethality hypotheses.
03
Checkpoint Inhibitor Resistance
Primary and acquired resistance, biomarker prediction and response mechanisms.
04
High-grade Lymphoma
First-line resistance, response assessment and subsequent treatment options.
05
Multiple Myeloma
Treatment sequencing, relapse, refractory state and prior-exposure tracking.

Paid evaluation pilot in precision oncology

One domain. Fixed protocol.

We benchmark current models on specialist-authored longitudinal cases and measure repeatable failure modes.

20–30longitudinal synthetic cases
8–12clinical and molecular-data tools
3–5model baselines
25%held-out evaluation split
Synthetic-patient research environment · not clinical decision support